IRWD 株価推移チャート
IRWD 財務
Ironwood Pharmaceuticals Inc
$3.91
5.39%
$0.2
終値： Jul 27, 16:00:00 GMT-4
$3.96
1.27%
$0.04
アフターマーケット：Jul 27, 19:50:33 GMT-4
戻る
Ironwood Pharmaceuticals Inc (IRWD) 財務
収入
貸借対照表
現金の流れ
年次
四半期
IRWD 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Ironwood Pharmaceuticals Incの主要な財務諸表は何ですか？
IRWDの主要な財務比率は何ですか？
Ironwood Pharmaceuticals Incの収益はセグメントまたは地域別にどのように分けられていますか？
Ironwood Pharmaceuticals Incは収益を上げていますか？
Ironwood Pharmaceuticals Incに負債はありますか？
Ironwood Pharmaceuticals Incの発行済株式数は何株ですか？
主要データ
前終値
$3.71
始値
$3.71
当日レンジ
$3.68 - $3.99
52週レンジ
$0.67 - $5.78
取引高
1.8M
平均取引高
2.5M
配当利回り
--
1株当たり利益(TTM)
0.58
時価総額
$651.8M
IRWDとは何ですか？
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
